(Date:5/16/2008)... Consumers could report side effects, but critics ...RIDAY, May 16 (HealthDay News) -- Direct-to-consum...ee phone number that would allow consumers to repo...sted Friday. , The experts serve on a panel tha...uch phone numbers are already mandated by the FDA ...
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHI... 500 paramedics,and emergency medical technicians ...hington area have ratified their first-ever contra... these workers are now covered by a,strong contrac...rement,future," said Teamsters General President J...
(Date:5/16/2008)... Study finds chronic disease sufferers gain benefi...AY, May 16 (HealthDay News) -- Taking activated vi...moderate to severe chronic kidney disease by about... two-year study of more than 1,400 patients, those...tivated vitamin D, had their overall risk of death...
(Date:5/16/2008)... PALM BEACH, Fla., May 16 /PRNewswire-USNewswi...ed more often by Americans, particularly our,child...9 individuals, have,significant hearing loss and t...n out of every 100 school age children have some f...tion to this social and economic problem,is what l...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3(Date:5/16/2008)..., -- Results demonstrating that TYKERB and trastu... extension of progression-free survival (PFS), --...he inside and,outside of the HER2 receptor may cre...trating activity of TYKERB alone despite patients,...umab and chemotherapy, LONDON and PHILADELPHIA, M...
(Date:5/16/2008)...s Statistically Significant Reductions in Selected...bstract to be published in 2008 Proceedings of the...nical Oncology, SAN DIEGO, May 16 /PRNewswire-Fir...ANX ) announced today that, in a registrational bi...a statistically significant reduction,in general d...
(Date:5/15/2008)...nical data highlight safety profile of BSI-201 in ...s -, BRISBANE, Calif., May 15 /- BiP...cal company developing novel cancer therapies,tod...hibitor, BSI-201, will,be presented at the 2008 Am... in Chicago., Findings will be presented from the...
(Date:5/15/2008)...ay 15 /- Schering-Plough,Co... science and treatment of,chronic hepatitis C viru...several clinical studies with PEGINTRON(TM) (pegin...combination therapy, as well as boceprevir, the,co...r, will be presented at,the 39th annual Digestive ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters 4742 1Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters 4742 2CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 1539 1CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 1539 2SIEMENS AlliedBarton Methodist Hospital and Family Planning Council Win Human Resources Department of the Year Awards 4738 1SIEMENS AlliedBarton Methodist Hospital and Family Planning Council Win Human Resources Department of the Year Awards 4738 2Blue Cross of California Reaches Out to Members Impacted by Southern California Fires 4734 1Blue Cross of California Reaches Out to Members Impacted by Southern California Fires 4734 2...STICALLY SIGNIFICANT CORRELATION BETWEEN,PLASMA LE...T , Management will host a conference call and liv...LO PARK, Calif. (March 19, 2007) – Corcept T...ounced that Study 06, the,last of three Phase 3 tr...features of Psychotic Major Depression (PMD), did ...
...Must Remain on the Millions Still Suffering from C... /PRNewswire/ -- The Centers for Disease,Control a...decline,in the rates of new acute hepatitis infect...flecting the success of hepatitis A and B,vaccinat...to,highlight these positive results, but remind pe...
Other Medicine Technology:Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 2Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 3Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 4Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint 5The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 2The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 3...ing more efficiency for high volume laboratories, ...provides extended walk away time. This high-speed ...up to 1600 photometric test results per hour (up t...ts on-board. Consolidate with Olympus 122 test men...
...Fit truly is a one size fits all plug. Once insert...inute period. As it hydrates, Form Fit increases i...licular cavity to form a perfect fit. ,The Form...nds into a soft, pliable, gelatinous material when...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma.
...ariLite dual wavelength (532 nm and 940 nm) laser ... This solid-state laser quickly and effectively tr...vulgaris. VariLite offers the clinical versatility...s deeper, larger vessels in a convenient, affordab...
Medicine Products: